Revisión fármaco-clínica en artrosis

• Autores: Josep Vergés Milano, Gemma Martínez, Eulàlia Montell, C. Coronas, Elena Tomás
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 5, Nº. 6, 2003, págs. 361-373
• Idioma: español
• Títulos paralelos:
  • Pharmaco-clinical revision in arthrosis
• Texto completo no disponible (Saber más ...)
• Resumen

  • The molecules considered effective in the treatment of osteoarthritis can be classified as of symptomatic action (slow or fast) and/or modifying action of the disease's course. Among molecules of symptomatic action, the following stand out due to their greater clinical experience: chondroitin sulfate, glucosamine sulfate and hyaluronic acid. In this article, the advantages of the clinical use of these molecules are explained, as well as their possible action mechanisms. It is understood as a molecule that is able to modify the course of the osteoarthritic disease, the molecule capable of preventing, delaying, stabilizing, repairing and/or reverting the injuries to the bone and the cartilage. In this revision, we are expose the first existing clinical evidences with chondroitin sulfate, glucosamine sulfate and hyaluronic acid about their potential to slow down the osteoarthritic process. Future clinical trials with a larger number of patients will have to confirm these promising preliminary results